The World Health Organization's recent declaration of Mpox as a Public Health Emergency of International Concern underscores the escalating threat posed by the Clade 1 strain of the Mpox virus, now spreading beyond Central Africa to Europe, Asia, and North America. GeoVax Labs, Inc. is responding to this crisis with the development of GEO-MVA, a U.S.-based MVA vaccine aimed at diversifying the global vaccine supply and enhancing pandemic preparedness.
With the global reliance on a single Mpox vaccine manufacturer posing significant risks to biosecurity and equitable distribution, GeoVax's GEO-MVA emerges as a strategic alternative. The vaccine is currently in the cGMP drug substance manufacturing phase, with clinical trials anticipated to begin in 2026. GEO-MVA's development utilizes an advanced continuous avian cell line manufacturing process, promising increased production yield, scalability, and cost-effectiveness, while eliminating dependency on pathogen-free chicken eggs.
David Dodd, Chairman & CEO of GeoVax, emphasized the importance of expanding domestic vaccine capacity to mitigate the risks of single-source dependency, especially in light of the Clade 1 strain's spread in the U.S. and globally. GeoVax is collaborating with U.S. federal agencies to align GEO-MVA with initiatives aimed at strengthening national pandemic readiness and onshoring critical pharmaceutical manufacturing.
The company advocates for accelerated regulatory pathways, expanded federal funding, and the preservation of early warning surveillance systems to ensure rapid scale-up and stockpiling of MVA-based vaccines. This development represents a critical step towards addressing the global Mpox threat, offering a scalable, cost-effective solution that supports national security and global health equity.
